首页> 外国专利> EDITING PROFILING OF PDE8A PRE -MRNA: USE AS SPECIFIC BIOMARKER OF ADARS ACTIVITIES IN HUMAN TISSUES TO DIAGNOSE AND TO PREDICT AND ASSESS THERAPEUTIC EFFICACY AND/OR EFFICIENCY OR POTENTIAL DRUG SIDE EFFECTS

EDITING PROFILING OF PDE8A PRE -MRNA: USE AS SPECIFIC BIOMARKER OF ADARS ACTIVITIES IN HUMAN TISSUES TO DIAGNOSE AND TO PREDICT AND ASSESS THERAPEUTIC EFFICACY AND/OR EFFICIENCY OR POTENTIAL DRUG SIDE EFFECTS

机译:PDE8A pre-MRNA的编辑特征:用作人类组织中ADAS活动的特定生物标记,以进行诊断和评估和评估治疗功效和/或功效或潜在药物副作用

摘要

The present invention relates to the use of the editing profile of PDE8A pre-mRNA as a specific bio marker of ADARs activities in evolved primate, particularly in Human tissues. The present invention also relates to an in vitro method for predicting in Human an alteration of the mechanism of the ADARs catalysed pre-mRNA editing of target genes, by analysing the PDE8A pre-mRNA editing profile in a peripheral tissue sample containing cells expressing said PDE8A pre-mRNA, such as blood sample. The present invention is also directed to an in vitro method for the screening of potential therapeutic compound and to predict and assess therapeutic efficacy and/or efficiency or to diagnose potential severe brain or peripheral drug side effects implementing said PDE8A pre-mRNA editing profile as specific biomarker. The present invention is further directed to a method for determining the PDE8A pre-mRNA editing profile in Human, particularly by capillary electrophoresis single-strand conformation polymorphism (CE-SSCP) method after amplification by a nested PCR. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR and kit comprising such sets of primers and human cells capable of expressing PDE8A and ADARs.
机译:本发明涉及PDE8A前mRNA的编辑谱作为进化的灵长类,特别是在人类组织中的ADARs活性的特异性生物标志物的用途。本发明还涉及一种体外方法,其通过分析包含表达所述PDE8A的细胞的外周组织样品中的PDE8A前mRNA编辑谱,在人体内预测ADAR催化的靶基因的前mRNA编辑机制的改变。前mRNA,例如血液样本。本发明还涉及用于筛选潜在的治疗性化合物并预测和评估治疗功效和/或效率或诊断以潜在的方式实施所述PDE8A前-mRNA编辑谱的潜在的严重脑或外周药物副作用的体外方法。生物标志物。本发明还涉及确定人中PDE8A前mRNA编辑谱的方法,特别是通过嵌套PCR扩增后,通过毛细管电泳单链构象多态性(CE-SSCP)方法。最后,本发明涉及在所述巢式PCR和试剂盒中实施的特定核酸引物,其包括这样的引物组和能够表达PDE8A和ADAR的人细胞。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号